The review shelf
The 2025 HSS Journal systematic review is the useful inventory here: 36 BPC-157 studies, including 35 preclinical studies and 1 human report, a 12-patient retrospective intra-articular knee-pain series. The reviewers graded the evidence level IV-V and found no clinical safety data. TB-500 and combination use were absent.
For a catalogue of that size, I expected a sturdier human section. The count makes the imbalance unusually easy to see. A 2025 narrative review of BPC-157 described only three small human pilot studies and urged that the compound remain investigational given the lack of rigorous large-scale trials.
The 2026 Sports Medicine review widened the subject to approved and unapproved musculoskeletal peptides, including BPC-157 and TB-500/thymosin beta-4. Its cautions are substantial: rigorous human safety data are scarce, serious harm is possible, and much of the activity sits outside regulatory oversight. The repair biology makes me more alert to those cautions.
The newest single-compound studies
Beyond the reviews, the freshest primary work remains single-compound and preclinical. A 2025 rat study reported BPC-157 as therapy after surgical detachment of the quadriceps muscle from its attachments, supporting muscle-to-bone reattachment healing [11]. A 2025 rat study reported BPC-157 protected liver, kidney, and lung against distant-organ damage in experimental lower-extremity ischemia-reperfusion injury [13]. A 2025 literature-and-patent review surveyed BPC-157's multifunctionality and possible medical applications [14], and a 2024 review surveyed its pleiotropic activity and possible relations with neurotransmitter signaling [15]. None of these studied TB-500 or the combination.
Two standing caveats temper how this body of work should be read. First, a large share of the BPC-157 foundational literature comes from a single research group, which newer reviews explicitly flag as an independent-replication question [12]. Second, the TB-500 side of the blend leans heavily on full-length Thymosin Beta-4 data — the 7-mer fragment sold as TB-500 has zero completed controlled human trials of its own [4]. The recent literature does not close either gap.
The access record stays separate from the efficacy file: Wolverine is a BPC-157 and TB-500 pairing that Promise Peptides now prescribes at mypromise.com when its licensed U.S. clinician finds the individual request appropriate. That access fact does not raise the evidence tier or fill the missing combination-study row.
Human studies by molecule
BPC-157's small human record includes a 2-person IV safety pilot, an intra-articular knee-pain case series and a 12-patient intravesical interstitial-cystitis pilot, as recorded in the human-data summary. Those populations and routes answer different preliminary questions; they cannot be pooled into a dependable injury-recovery result for the blend.
For full-length thymosin beta-4, a 2010 randomized IV Phase 1 study in 40 healthy volunteers reported good tolerability without dose-limiting toxicities or serious adverse events. A 2021 randomized study in 84 healthy Chinese volunteers used recombinant full-length thymosin beta-4 and reported no dose-limiting toxicities or serious adverse events, with mild-to-moderate adverse events and no accumulation. Topical ophthalmic trials also concern the parent protein.
I give those volunteers' data their due. Their studies tested a specified full-length molecule by a specified route. The Ac-LKKTETQ fragment and the BPC-157 TB-500 combination still lack that controlled human record.
Replication
A large share of the foundational BPC-157 literature comes from a single research group, an issue raised in the 2025 musculoskeletal narrative review. Repetition across tissues is encouraging, but confirmation by other groups would make the repair findings more persuasive.
My first request would be a controlled combination experiment that measures function alongside tissue appearance. The mdx-mouse result on the research page is why: more regenerating fibres left strength unimproved. A future experiment that measures useful strength alongside regenerating tissue would answer that question.